Article L.233-8 II of the French Code of Commerce
Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers
Regulatory News:
Safe Orthopaedics (Paris:SAFOR):
Date | Total number of shares | Number of voting rights | Number of voting rights | |||||||||||
December 31, 2018 | 41 268 022 | 47 038 207 | 46 941 819 |
total number of voting rights calculated on the basis of all shares to which voting rights are attached, including those that do not have voting rights.
Next publication: 2018 full-year results and first-quarter 2019 revenues, April 26, 2019(after the market close)
About Safe Orthopaedics:
Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the SteriSpine Kits are CE-marked and FDA cleared. The company is based at Eragny-sur-Oise (France), and has 43 employees.
For more information, visit: www.safeorthopaedics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190117005031/en/
Contacts:
Safe Orthopaedics
François-Henri Reynaud
Directeur Administratif Financier
Phone: +33 (0)1 34 21 50 00
investors@safeorthopaedics.com
Investor Relations
NewCap
Valentine Brouchot
Phone: +33 (0)1 44 71 94 94 SafeOrtho@newcap.eu
Relations Presse
Ulysse Communication
Bruno Arabian
Phone: +33 (0)6 87 88 47 26 barabian@ulysse-communication.com
Nicolas Daniels
Phone: +33 (0)6 63 66 59 22 ndaniels@ulysse-communication.com